Holen Sie sich die Stockscreener-App
1.75
1.13%
-0.02
Handel nachbörslich:
1.75
Schlusskurs vom Vortag:
$1.77
Offen:
$1.75
24-Stunden-Volumen:
18,910
Relative Volume:
1.84
Marktkapitalisierung:
$20.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-3.15M
KGV:
-5.7339
EPS:
-0.3052
Netto-Cashflow:
$-2.23M
1W Leistung:
-4.89%
1M Leistung:
-20.81%
6M Leistung:
-30.00%
1J Leistung:
+1.16%
1-Tages-Spanne:
$1.73
$1.78
1-Wochen-Bereich:
$1.73
$1.8784
52-Wochen-Spanne:
$1.20
$4.0499
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Firmenname
Cytomed Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GDTC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
1.75 | 20.43M | 0 | -3.15M | -2.23M | -0.3052 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomed Therapeutics Ltd Aktie (GDTC) Neueste Nachrichten
Real time scanner hits for CytoMed Therapeutics Limited explained2025 Price Momentum & Risk Controlled Daily Trade Plans - Newser
Is CytoMed Therapeutics Limited a candidate for recovery playRisk Aware Trading Ideas with Alert Levels - Newser
CytoMed Therapeutics (NASDAQ:GDTC) Trading Down 3.7% – Here’s What Happened - Defense World
Comparing CytoMed Therapeutics Limited in custom built stock radarsAI Pattern Recognition and Trade Prediction - Newser
How high can CytoMed Therapeutics Limited stock price go in 2025Buy and Hold Strategy for Capital Safety - Newser
CytoMed Therapeutics Limited stock trendline breakdownMonthly Long-Term Market Recap and Summary - Newser
Is it time to cut losses on CytoMed Therapeutics LimitedFree Momentum Based Equity Trading Plan - Newser
Is CytoMed Therapeutics Limited Stock Overbought or Oversold RSI Indicator AnalysisAlgorithmic Prediction of Market Breakouts - Newser
Published on: 2025-07-29 02:23:22 - metal.it
Does CytoMed Therapeutics Limited stock perform well during market downturnsCapitalize on trading strategies that deliver - Jammu Links News
What is the risk reward ratio of investing in CytoMed Therapeutics Limited stockUnrivaled growth potential - Jammu Links News
Price momentum metrics for CytoMed Therapeutics Limited explainedTechnical Trade Plan with Entry Checklist - Newser
What are analysts’ price targets for CytoMed Therapeutics Limited in the next 12 monthsCapitalize on fast-moving stock opportunities - Jammu Links News
CytoMed Therapeutics Limited Stock Analysis and ForecastMarket-leading growth rates - Autocar Professional
What drives CytoMed Therapeutics Limited stock priceExplosive market performance - jammulinksnews.com
Is CytoMed Therapeutics Limited a good long term investmentRapid-fire capital growth - jammulinksnews.com
What drives SDST stock priceConsistently profitable trades - Autocar Professional
The ANGELICA Trial and the Future of Allogeneic CAR-T: A Strategic Investment Perspective - AInvest
CytoMed's Breakthrough Cancer Cell Therapy Shows Promise in Phase 1 Trial, Advances to Higher Dose Testing - Stock Titan
GDTC advances CTM-N2D: Dose Level 1 complete, Phase I escalates | GDTC SEC FilingForm 6-K - Stock Titan
COST Stock Analysis and ForecastFree Investment Community - jammulinksnews.com
Blue Chip Stocks High Precision Stock TipsBreakthrough stock performance - jammulinksnews.com
What analysts say about CytoMed Therapeutics Limited stockExceptional profit velocity - jammulinksnews.com
How CytoMed Therapeutics Limited stock performs during market volatilitySmart Money Trade Setups - Newser
What makes CytoMed Therapeutics Limited stock price move sharplySafe and Scalable Investment Tips - Newser
Why CytoMed Therapeutics Limited stock attracts strong analyst attentionTrade With Low Risk Exposure - Newser
CytoMed Therapeutics shareholders approve all proposals at annual meeting By Investing.com - Investing.com Nigeria
CytoMed Therapeutics shareholders approve all proposals at annual meeting - Investing.com
The Pipeline for of iPSC-Derived Cell Therapeutics in 2025 - BioInformant
Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shel - GuruFocus
CytoMed Therapeutics Files $50 Million Mixed Shelf - MarketScreener
Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shelf Offering | GDTC Stock News - GuruFocus
CytoMed Therapeutics schedules annual shareholder meeting - Investing.com Australia
CytoMed Therapeutics schedules annual shareholder meeting By Investing.com - Investing.com India
CytoMed Therapeutics (NASDAQ:GDTC) Stock Price Down 0.4% – Here’s Why - Defense World
CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript
CytoMed Therapeutics Reports Full Year Ended December 31, - GlobeNewswire
CytoMed 2024 Results: 39% Lower Losses as Biotech Advances Novel Cancer Cell Therapy Trial - Stock Titan
Cytomed Therapeutics Ltd shares rise 3.08% intraday after Osteopore secures EU approval for custom orthopaedic and cranial implants. - AInvest
Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight - The Globe and Mail
Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight - GlobeNewswire
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - ACCESS Newswire
Finanzdaten der Cytomed Therapeutics Ltd-Aktie (GDTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):